2019 WMS Abstract – 48-Week Changes in NSAA

Consistency of 48-week changes in North Star Ambulatory Assessment (NSAA) between Duchenne muscular dystrophy (DMD) natural history data and clinical trial placebo arms, after adjustment for prognostic factors View the Full PDF

cTAP Partner Wins ISPOR Award on Duchenne Muscular Dystrophy

Published December 5, 2018 The collaborative Trajectory Analysis Project (cTAP), a multi-stakeholder, non-competitive global coalition in Duchenne muscular dystrophy, today announced that Analysis Group Managing Principal James Signorovitch, cTAP’s partner, has been selected as recipient of ISPOR’s “Best General Research Podium Presentation” award at ISPOR Europe 2018, which recently took place in Barcelona, Spain. Dr. Signorovitch’s research presentation titled Ambulatory Function in Duchenne Muscular Dystrophy (DMD): The Characteristic Trajectory and Variation Across Individuals, will be...